Upstream Bio reports Phase 2 VIBRANT trial gains for verekitug in nasal polyps

Reuters

Yesterday

Upstream Bio reports Phase 2 VIBRANT trial gains for verekitug in nasal polyps

Upstream Bio Inc. reported additional analyses from its Phase 2 VIBRANT trial (NCT06164704) evaluating verekitug in 81 adults with chronic rhinosinusitis with nasal polyps over 24 weeks. The new analyses adjusted for concomitant rescue therapy use using a worst-observation carried-forward approach and showed a placebo-adjusted reduction in endoscopic nasal polyp score of -1.95 (p < 0.0001) and a reduction in nasal congestion score of -0.96 (p < 0.0001) at week 24; the company also reiterated previously reported data showing a 76% reduction in the need for surgery or systemic corticosteroids versus placebo (p = 0.03). These additional results were presented at the AAAAI 2026 Annual Meeting, and the company said planning has begun for Phase 3 trials in chronic rhinosinusitis with nasal polyps and severe asthma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603010945PRIMZONEFULLFEED9663439) on March 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2616201618"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616201618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616201618?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-01 22:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616201618","market":"fut","top_or_hot":-1,"title":"Upstream Bio reports Phase 2 VIBRANT trial gains for verekitug in nasal polyps","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Upstream Bio reports Phase 2 VIBRANT trial gains for verekitug in nasal polyps\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Upstream Bio Inc. reported additional analyses from its Phase 2 VIBRANT trial (NCT06164704) evaluating verekitug in 81 adults with chronic rhinosinusitis with nasal polyps over 24 weeks. The new analyses adjusted for concomitant rescue therapy use using a worst-observation carried-forward approach and showed a placebo-adjusted reduction in endoscopic nasal polyp score of -1.95 (p &lt; 0.0001) and a reduction in nasal congestion score of -0.96 (p &lt; 0.0001) at week 24; the company also reiterated previously reported data showing a 76% reduction in the need for surgery or systemic corticosteroids versus placebo (p = 0.03). These additional results were presented at the AAAAI 2026 Annual Meeting, and the company said planning has begun for Phase 3 trials in chronic rhinosinusitis with nasal polyps and severe asthma.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603010945PRIMZONEFULLFEED9663439) on March 01, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Upstream Bio reports Phase 2 VIBRANT trial gains for verekitug in nasal polyps</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpstream Bio reports Phase 2 VIBRANT trial gains for verekitug in nasal polyps\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-01 22:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Upstream Bio reports Phase 2 VIBRANT trial gains for verekitug in nasal polyps\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Upstream Bio Inc. reported additional analyses from its Phase 2 VIBRANT trial (NCT06164704) evaluating verekitug in 81 adults with chronic rhinosinusitis with nasal polyps over 24 weeks. The new analyses adjusted for concomitant rescue therapy use using a worst-observation carried-forward approach and showed a placebo-adjusted reduction in endoscopic nasal polyp score of -1.95 (p &lt; 0.0001) and a reduction in nasal congestion score of -0.96 (p &lt; 0.0001) at week 24; the company also reiterated previously reported data showing a 76% reduction in the need for surgery or systemic corticosteroids versus placebo (p = 0.03). These additional results were presented at the AAAAI 2026 Annual Meeting, and the company said planning has begun for Phase 3 trials in chronic rhinosinusitis with nasal polyps and severe asthma.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603010945PRIMZONEFULLFEED9663439) on March 01, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014021.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nNDL3YqRrf:1","article_id":"2616201618","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616201618","pubTimestamp":1772376320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Upstream Bio Inc. reported additional analyses from its Phase 2 VIBRANT trial  evaluating verekitug in 81 adults with chronic rhinosinusitis with nasal polyps over 24 weeks. The new analyses adjusted for concomitant rescue therapy use using a worst-observation carried-forward approach and showed a placebo-adjusted reduction in endoscopic nasal polyp score of -1.95  and a reduction in nasal congestion score of -0.96  at week 24; the company also reiterated previously reported data showing a 76% reduction in the need for surgery or systemic corticosteroids versus placebo . These additional results were presented at the AAAAI 2026 Annual Meeting, and the company said planning has begun for Phase 3 trials in chronic rhinosinusitis with nasal polyps and severe asthma.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","UPB":"UpStream Bio Inc.","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Upstream Bio报告verekitug治疗鼻息肉的2期试验取得了积极成果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"UPB":0.9},"content_text":"Upstream Bio reports Phase 2 VIBRANT trial gains for verekitug in nasal polyps\n    \n\n        Upstream Bio Inc. reported additional analyses from its Phase 2 VIBRANT trial (NCT06164704) evaluating verekitug in 81 adults with chronic rhinosinusitis with nasal polyps over 24 weeks. The new analyses adjusted for concomitant rescue therapy use using a worst-observation carried-forward approach and showed a placebo-adjusted reduction in endoscopic nasal polyp score of -1.95 (p < 0.0001) and a reduction in nasal congestion score of -0.96 (p < 0.0001) at week 24; the company also reiterated previously reported data showing a 76% reduction in the need for surgery or systemic corticosteroids versus placebo (p = 0.03). These additional results were presented at the AAAAI 2026 Annual Meeting, and the company said planning has begun for Phase 3 trials in chronic rhinosinusitis with nasal polyps and severe asthma.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603010945PRIMZONEFULLFEED9663439) on March 01, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}